A A Forastiere

2.6k total citations · 1 hit paper
14 papers, 2.0k citations indexed

About

A A Forastiere is a scholar working on Otorhinolaryngology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, A A Forastiere has authored 14 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Otorhinolaryngology, 8 papers in Pulmonary and Respiratory Medicine and 6 papers in Oncology. Recurrent topics in A A Forastiere's work include Head and Neck Cancer Studies (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Lung Cancer Research Studies (3 papers). A A Forastiere is often cited by papers focused on Head and Neck Cancer Studies (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Lung Cancer Research Studies (3 papers). A A Forastiere collaborates with scholars based in United States and Canada. A A Forastiere's co-authors include Jay S. Cooper, K.K. Fu, Wael Sakr, Muhyi Al‐Sarraf, John F. Ensley, T. Vuong, Dorit Elisabeth Schuller, Michael LeBlanc, George L. Adams and Padmini Giri and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Radiotherapy and Oncology.

In The Last Decade

A A Forastiere

13 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.

1998 1.7k citations Muhyi Al‐Sarraf, Michael LeBlanc et al. Journal of Clinical Oncology profile →

Peers

A A Forastiere

OTORH

SURGE

ONCOL

PRM

MB

Padmini Giri United States

T. Vuong Canada

A. Trotti United States

Mary Ellyn Witt United States

Roger K.C. Ngan China

A Rey France

Henry Sze China

Fred Rosen United States

Halvor Vermund United States

J.L. Geiger United States

Padmini Giri United States

A A Forastiere

1.4k ×0.9

OTORH

1.1k ×0.9

SURGE

911 ×1.0

ONCOL

590 ×1.0

PRM

195 ×0.8

MB

Citations per year, relative to A A Forastiere A A Forastiere (= 1×) peers Padmini Giri

Countries citing papers authored by A A Forastiere

Since Specialization

Citations

This map shows the geographic impact of A A Forastiere's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A A Forastiere with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A A Forastiere more than expected).

Fields of papers citing papers by A A Forastiere

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A A Forastiere. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A A Forastiere. The network helps show where A A Forastiere may publish in the future.

Co-authorship network of co-authors of A A Forastiere

This figure shows the co-authorship network connecting the top 25 collaborators of A A Forastiere. A scholar is included among the top collaborators of A A Forastiere based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A A Forastiere. A A Forastiere is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

1.

Forastiere, A A, Moshe Maor, Andy Trotti, et al.. (2013). SP-004: Long Term Results of Intergroup RTOG 91-11: A Comparison of Three Treatments to Preserve the Larynx. Radiotherapy and Oncology. 106. S1–S2. 1 indexed citations

2.

Forastiere, A A. (2011). VALUE BASED CANCER CARE. Radiotherapy and Oncology. 98. S15–S15.

3.

O’Meara, Elizabeth, Mitchell Machtay, Jennifer Moughan, et al.. (2007). Associations between Radiation Doses to Pharyngeal Regions and Severe Late Toxicity in Head and Neck Cancer Patients Treated With Concurrent Chemoradiotherapy–An RTOG Analysis. International Journal of Radiation Oncology*Biology*Physics. 69(3). S54–S55. 6 indexed citations

4.

Cooper, Jay S., Thomas F. Pajak, A A Forastiere, et al.. (2006). 25. International Journal of Radiation Oncology*Biology*Physics. 66(3). S14–S15. 8 indexed citations

5.

Argiris, Athanassios, et al.. (2004). Prognostic factors and long-term survivorship in patients with recurrent or metastatic head and neck cancer (HNC): An analysis of two Eastern Cooperative Oncology Group (ECOG) randomized trials. Journal of Clinical Oncology. 22(14_suppl). 5514–5514. 2 indexed citations

6.

Murphy, Barbara A., Traci Leong, Brian B. Burkey, Corey J. Langer, & A A Forastiere. (2001). Lack of Efficacy of Topotecan in the Treatment of Metastatic or Recurrent Squamous Carcinoma of the Head and Neck. American Journal of Clinical Oncology. 24(1). 64–66. 4 indexed citations

7.

Shiga, Hideaki, Elisabeth I. Heath, Audrey Rasmussen, et al.. (1999). Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.. PubMed. 5(12). 4097–104. 104 indexed citations

8.

Flood, William A., A. Trotti, Barbara A. Murphy, et al.. (1999). Multimodality therapy of patients with locally advanced squamous cell cancer of the head and neck: preliminary results of two pilot trials using paclitaxel and cisplatin.. PubMed. 9(2 Suppl 1). 64–9. 13 indexed citations

9.

Al‐Sarraf, Muhyi, Michael LeBlanc, Padmini Giri, et al.. (1998). Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.. Journal of Clinical Oncology. 16(4). 1310–1317. 1695 indexed citations breakdown →

10.

Giri, P.G. Shankar, M. Leblanc, Muhyi Al‐Sarraf, et al.. (1996). 8 Improved survival with chemotherapy and radiation therapy versus radiation therapy alone in advanced nasopharyngeal cancer. Preliminary results of an intergroup randomized trial. Int 0099, SWOG 8892, RTOG 8817, ECOG 2388. International Journal of Radiation Oncology*Biology*Physics. 36(1). 162–162. 9 indexed citations

11.

Forastiere, A A. (1994). Overview of platinum chemotherapy in head and neck cancer.. PubMed. 21(5 Suppl 12). 20–7. 51 indexed citations

12.

Forastiere, A A. (1994). Current and future trials of Taxol (paclitaxel) in head and neck cancer.. PubMed. 5 Suppl 6. S51–4. 16 indexed citations

13.

Forastiere, A A, et al.. (1988). Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients.. PubMed. 48(13). 3869–74. 70 indexed citations

14.

Aisner, Joseph, A A Forastiere, & R. S. Aroney. (1983). Patterns of recurrence for cancer of the lung and esophagus. 2. 87–105. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact